Gross margin -- 57.9%, which declined by 250 basis points year over year because of product mix shifts and elevated ...

Results from an interim analysis in the Phase 2 STARBORN-1 trial of TARA-002 in pediatric LMs patients remain on track for 4Q 2025Expect to ...